Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer

Natacha Bordry, Alfredo Addeo, Cyril Jaksic, Valérie Dutoit, Pascale Roux-Lombard, Dimpy P. Shah, Pankil K. Shah, Angèle Gayet-Ageron, Alex Friedlaender, Sébastien Bugeia, Garance Gutknecht, Anna Battagin, Maragrazia Di Marco, Pierre Francois Simand, Intidhar Ladibi-Galy, Sarah Fertani, José Sandoval, Pierre Yves Dietrich, Nicolas Mach

Research output: Contribution to journalArticlepeer-review

Abstract

Little is known on the long-lasting humoral response and the T cell activation induced by SARS-CoV-2 mRNA vaccines in patients with cancer. The study assessed the efficacy of the SARS-CoV-2 mRNA vaccines through measuring the seroconversion rate at pre-specified time points and the effect on the T cell immunity in patients with cancers. The study included 131 adult patients with solid or hematological cancer, who received SARS-CoV-2 mRNA vaccines. 96.2% of them exhibited adequate antibody response to the SARS-CoV-2 mRNA vaccines 2 months after the booster dose. SARS-CoV-2 mRNA vaccines could induce T cell activation; however, this is more likely in patients who have a positive seroconversion (94%) compared with the patients who did not (50%). Further research into the clinical relevance of low antibodies titers and lack of T cell activity is required to set up an effective vaccination strategy within this group of patients.

Original languageEnglish (US)
Article number103699
JournaliScience
Volume25
Issue number1
DOIs
StatePublished - Jan 21 2022
Externally publishedYes

Keywords

  • Biological sciences
  • Immune response
  • Virology

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer'. Together they form a unique fingerprint.

Cite this